Skip to content

An observational study of Guduchi Extract Tablet

Evaluation of Efficacy and Safety of Guduchi (Tinospora cordifolia) Extract Tablet in Healthy Population during COVID-19 Pandemic-An open label single arm Non randomized Observational Study.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/08/027034
Enrollment
1200
Registered
2020-08-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Nil: Nil

Sponsors

Central council for Research in Ayurvedic Sciences Ministry of AYUSH Govt of India New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Healthy individuals (male &female) subject between the age group of 18-70 years who are living in Jodhpur city. 2. Those who do not have any acute medical condition or chronic medical/surgical condition that requires either immediate or continuous medical monitoring or treatment will be treated as Healthy individuals. 3. Participants who can take medicines orally.

Exclusion criteria

Exclusion criteria: 1. Cases of severe vomiting which would affect oral administration of medicine difficult. 2. Positive COVID-19 patient (asymptomatic/symptomatic/mild) 3. Cases of respiratory failure and requiring mechanical ventilation. 4. Combined organ failure requiring ICU monitoring. 5. Patients with uncontrolled Diabetes Mellitus, (HbA1c more than 8.0), Malignant Hypertension (systolic BP more than 180 and diastolic 110), Chronic Renal Failure and those on immunosuppressive medication. 6. Pregnant and Lactating females 7. Any other condition, which as per the investigator would jeopardize the outcome of the trial.

Design outcomes

Primary

MeasureTime frame
1. Prevention of incidence of COVID-19 in subjects taking Guduchi Extract Tablet. 2. Prevention of incidence of non-specific symptoms such as fever, fatigue, cough anorexia, malaise, muscle pain, sore throat, dyspnea, nasal congestion, or headache. Timepoint: 15 days

Secondary

MeasureTime frame
1. Number of cases Reporting any ADR/AE 2. Number of patients referred. Timepoint: 15 days

Countries

India

Contacts

Public ContactDr Sanjay Srivastava

Dr. S.R. Rajasthan Ayurved University, Jodhpur

vc.dsrrau@gmail.com8800543828

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026